IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update slide image

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

IDE397 Next Steps and Phase 1 Program Summary Key Upcoming Milestones • Targeting to deliver GSK Option Data Package Mid-Year 2022 - Potential $50 million Option Exercise Fee • Targeting to initiate IDE397 Monotherapy Expansion and Combination Escalation Cohorts Mid-Year 2022 - Mono Expansion Cohorts to include NSCLC and Combinations with Taxanes and other Standard of Care Combination Agents IDE397 Phase 1 Interim Clinical Data Summary • Favorable PK profile supports acceptable dosing regimen • • • • No drug-related SAEs observed through Cohort 5 and MTD not yet observed Robust plasma SAM and exposure dependent tumor pharmacodynamics observed in target tumor types Cohort 6 enrollment ongoing; first patient cleared without DLT Favorable Preliminary Risk / Benefit Profile vs. Historical - IDE397: Observed preliminary signals of clinical activity, including robust pharmacodynamic modulation and tumor shrinkage Dose-proportional exposure across all Cohorts 1 through 5 with favorable drug exposure relative to AE profile MTD not yet observed with no drug-related SAEs through Cohort 5 GSK PRMT5: 26% SAES (53% Grade 3/4) at 400mg QD Expansion Dose (n=19)* AG-270: 18% Grade 3 or higher AE at 200mg QD Expansion Dose (n=11), and 67% Grader 3 or higher AE at 200mg BID (n=6)** 16 * ESMO 2019; ** AACR-NCI-EROTC Triple Meeting, 2019, DCR = Disease Control Rate gsk BIOSCIENCES IDEAVA
View entire presentation